Aller au contenu principal
Accès ouvert déclaré 2025 article

Human Papillomavirus ( HPV ) Screening With Universal Access to Vaginal Self‐Testing: Outcomes of an Implementation Trial

6Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : nz. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

OBJECTIVE: Determine the feasibility of high-risk human papillomavirus (HPV)-based cervical screening that included the option of a vaginal swab HPV test (vaginal self-test). DESIGN: Implementation trial. SETTING: 17 primary care practices. POPULATION OR SAMPLE: People due for a cervical screening test. METHODS: Participants could choose a clinician-taken cervical test or a vaginal self-test (undertaken in clinic or at home), unless a cervical co-test (HPV and cytology) was clinically indicated. MAIN OUTCOME MEASURES: Proportion of participants who had (a) a vaginal self-test, (b) an HPV-detected result and (c) HPV detected on a vaginal self-test and returned for further investigation. RESULTS: 3121 people were enrolled. Participation rates were high for people of all recorded ethnicities. A vaginal self-test was undertaken by 95% (2954/3121, 95% confidence interval [CI] [93.8, 95.4]) of people. HPV was detected in 12.9% (404/3121, 95% CI [11.8, 14.2]) of people. 95% (384/404, 95% CI [92.5, 97.0]) of people with HPV detected had follow-up cytology or colposcopy. 2.6% (82/3121, 95% CI [2.1, 3.2]) had HPV 16/18 detected, all of whom attended colposcopy. Cytology triage was completed for 92% (276/301, 95% CI [88.0, 94.3]) of people with non-16/18 HPV types (HPV other) detected on a vaginal self-test. This varied by ethnicity and screening history. CONCLUSION: This study confirms the feasibility of cervical screening with the universal option of a vaginal self-test and demonstrated a clear preference for the vaginal self-test. Challenges remain in relation to equitable provision of cytology triage. Ongoing programme monitoring is imperative. TRIAL REGISTRATION: Australia and New Zealand Clinical Trial Register. ANZCTR Reference number: ACTRN12622000699763 (https://anzctr.org.au/).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Human Papillomavirus (<scp>HPV</scp>) Screening With Universal Access to Vaginal Self‐Testing: Outcomes of an Implementation Trial
Date Crossref
31/03/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.